3Wu M, Lu YB,Jiang B, et al. Effects of methyprednisolone and proinflammatory activation D activity of leukocytes in systemic inflammatory response induced by cardiopulmonary bypass. Acta Pharmacol Sin, 2001,22(10): 913～917.
1[1]Haslam PL,Baker CS,Hughes DA,et al.Pulmonary surfactant composition early in development of acute lung injury after cardiopulmonary bypass:prophylactic use of surfactant therapy[J].Int J Exp Pathol,1997,78(4):277-289.
2[2]LeVine AM, Lotze A, Stanley S,et al. Surfactant content in children with inflammatory lung disease[J].Crit Care Med,1996,24(6):1062-1067.
3[3]Griese M. Pulmonary surfactant in health and human lung diseases: state of the art[J]. Eur Respir J,1999,13(6):1455-1476.
4[4]Chai PJ, Williamson JA, Lodge AJ,et al. Effects of ischemia on pulmonary dysfunction after cardiopulmonary bypass[J]. Ann Thorac Surg,1999,67(3):731-735.
5[5]Millar KJ,Dargaville PA,South M,et al.Pulmonary surfactant and cardiopulmonary bypass in infants[J]. J Thorac Cardiovasc Surg,2000,119(1):192-195.
7[7]Raymondos K, Leuwer M, Haslam PL,et al. Compositional, structural, and functional alterations in pulmonary surfactant in surgical patients after the early onset of systemic inflammatory response syndrome or sepsis[J].Crit Care Med,1999,27(1):12-13.
8[8]Cane RD, Neymour R. Pulmonary surfactant in acute lung injury[J].Crit Care Med,1999,27(1):82-89.
9[9]Griese M, Wilnhammer C, Jansen S,et al. Cardiopulmonary bypass reduces pulmonary surfactant activity in infants[J].J Thorac Cardiovasc Surg,1999,118(2):237-244.
10[10]Paul DA, Greenspan JS, Davis DA,et al.The role of cardiopulmonary bypass and surfactant in pulmonary decompensation after surgery for congenital heart disease[J].J Thorac Cardiovasc Surg,1999,117(5):1025-1026.
